

**Supplemental Table 4: Reactogenicity Per Dose Analysis for Unimputed Safety Population Data
In Clinic Exam Data Local Endpoints
Fisher's Exact Test Comparing TRT-8IM to TRT-8SQ**

Adverse Event (AE) Endpoint	Dose	Fisher's 2-sided P-value	Percent with AE in TRT-8SQ	Percent with AE in TRT-8IM
Warmth	1	<.0001	28.69	3.63
	2	<.0001	40.56	7.72
	3	<.0001	32.26	6.15
	4	<.0001	38.79	12.99
	5	<.0001	34.25	13.39
	6	<.0001	39.53	15.35
	7	<.0001	50.76	19.51
	8	<.0001	49.40	20.94
Tenderness	1	0.0002	63.49	46.64
	2	<.0001	72.11	54.80
	3	0.0002	47.56	31.02
	4	<.0001	64.81	41.88
	5	0.0107	53.36	40.97
	6	0.0002	57.21	38.71
	7	0.0001	61.22	41.75
	8	0.0002	63.10	43.52
Itching	1	0.2213	2.83	1.21
	2	<.0001	15.73	1.63
	3	<.0001	22.67	4.12
	4	<.0001	19.91	6.55
	5	0.0040	17.27	8.04
	6	<.0001	22.43	6.05
	7	0.0001	25.13	10.19
	8	<.0001	26.19	9.42
Pain	1	0.2000	15.66	20.48
	2	0.5795	21.69	19.51
	3	1.0000	11.84	12.20
	4	0.4658	19.21	16.38
	5	0.7898	15.53	14.22
	6	0.8894	13.49	14.42
	7	1.0000	17.95	18.05
	8	0.6840	19.76	17.62
AML	1	1.0000	8.06	8.43

*=TRT-8SQ>TRT-8IM, p<0.05, **TRT-8IM>TRT-8SQ, p<0.05, NA=Not enough data

**Supplemental Table 4: Reactogenicity Per Dose Analysis for Unimputed Safety Population Data
In Clinic Exam Data Local Endpoints
Fisher's Exact Test Comparing TRT-8IM to TRT-8SQ**

Adverse Event (AE) Endpoint	Dose	Fisher's 2-sided P-value	Percent with AE in TRT-8SQ	Percent with AE in TRT-8IM
	2	0.7848	11.65	12.50
	3	1.0000	5.33	5.35
	4	1.0000	11.35	11.69
	5	0.5403	9.59	11.50
	6	0.0066	5.14	13.08
	7	0.4003	8.21	10.73
	8	0.0095	4.79	13.09
Erythema	1	<.0001	52.99	14.00
	2	<.0001	63.75	23.89
	3	<.0001	57.43	23.36
	4	<.0001	64.98	33.19
	5	<.0001	63.51	39.82
	6	0.0007	63.59	47.25
	7	<.0001	67.51	46.15
	8	<.0001	71.01	41.15
Induration	1	<.0001	25.51	5.65
	2	<.0001	34.54	9.76
	3	<.0001	27.76	8.57
	4	<.0001	40.43	12.66
	5	<.0001	38.18	12.50
	6	0.0001	36.11	19.35
	7	<.0001	37.76	13.17
	8	0.0002	34.52	17.28
Edema	1	<.0001	17.27	4.82
	2	<.0001	33.20	12.60
	3	<.0001	31.05	11.93
	4	0.0014	32.47	19.13
	5	0.1139	31.36	24.55
	6	0.3043	34.88	29.95
	7	0.5305	36.92	33.66
	8	<.0001	45.51	25.39
Nodule	1	<.0001	38.55	3.63
	2	<.0001	42.17	3.25

*=TRT-8SQ>TRT-8IM, p<0.05, **TRT-8IM>TRT-8SQ, p<0.05, NA=Not enough data

**Supplemental Table 4: Reactogenicity Per Dose Analysis for Unimputed Safety Population Data
In Clinic Exam Data Local Endpoints
Fisher's Exact Test Comparing TRT-8IM to TRT-8SQ**

Adverse Event (AE) Endpoint	Dose	Fisher's 2-sided P-value	Percent with AE in TRT-8SQ	Percent with AE in TRT-8IM
	3	<.0001	35.89	4.53
	4	<.0001	25.76	5.68
	5	<.0001	26.24	9.33
	6	<.0001	23.15	7.48
	7	0.0002	21.13	7.77
	8	<.0001	26.51	3.66
Bruise	1	1.0000	6.10	6.45
	2	0.2505	7.26	4.45
	3	0.5464	6.10	4.53
	4	0.5455	6.11	4.78
	5	0.5410	2.73	1.79
	6	0.1576	6.05	2.80
	7	0.5318	5.13	6.83
	8	0.0434	6.06	1.58
Presence or Absence of Local AEs	1	<.0001	81.10	57.81
	2	<.0001	88.89	67.73
	3	<.0001	80.08	52.82
	4	<.0001	84.45	64.26
	5	0.0033	81.33	69.30
	6	0.0002	84.40	69.37
	7	0.0054	84.34	72.60
	8	<.0001	91.76	72.02
Presence or Absence of Moderate/Severe Local AEs	1	0.3465	6.88	4.84
	2	0.0026	15.73	6.91
	3	0.0539	8.16	3.70
	4	0.0383	12.61	6.52
	5	0.0123	9.55	3.57
	6	0.3117	7.48	4.67
	7	0.0876	11.86	6.83
	8	0.4249	13.77	10.94
Presence or Absence of Local Large AEs	1	NA	0.00	0.00
	2	1.0000	0.81	0.41
	3	0.4171	3.69	2.06

*=TRT-8SQ>TRT-8IM, p<0.05, **TRT-8IM>TRT-8SQ, p<0.05, NA=Not enough data

**Supplemental Table 4: Reactogenicity Per Dose Analysis for Unimputed Safety Population Data
In Clinic Exam Data Local Endpoints
Fisher's Exact Test Comparing TRT-8IM to TRT-8SQ**

Adverse Event (AE) Endpoint	Dose	Fisher's 2-sided P-value	Percent with AE in TRT-8SQ	Percent with AE in TRT-8IM
	4	0.2157	2.18	0.44
	5	0.1755	0.91	3.13
	6	0.5751	2.34	3.72
	7	0.3826	2.06	3.90
	8	0.7783	4.24	3.16

**=TRT-8SQ>TRT-8IM, p<0.05, **TRT-8IM>TRT-8SQ, p<0.05, NA=Not enough data*